:
| Patent | Priority date | Main claims | |--------|---------------|-------------| | | 15 Jan 2022 | Claims a series of fluoro‑aryl pyrimidine kinase inhibitors covering JUQ‑470, with specific substitution patterns on the aromatic ring and heterocycle. | | US2023/098765 | 3 Mar 2023 | Claims the pharmacological use of JUJ‑470 (and analogs) for treatment of FGFR‑driven and angiogenesis‑dependent cancers. | | US2024/014321 (filed 2024) | 21 Jun 2024 | Claims combination regimens of JUQ‑470 with immune checkpoint inhibitors (PD‑1/PD‑L1 antibodies). | JUQ-470
These clinical data are preliminary and have not yet been peer‑reviewed. The trial is still recruiting in several sites across North America and Europe. : | Patent | Priority date | Main
The same alphanumeric tag can be repurposed across industries; the most credible, repeatable mentions are the and sensor contexts. | These clinical data are preliminary and have
The term "JUQ-470" appears to be associated with a specific topic, but without further context, it's challenging to provide a detailed explanation. After conducting research, I found that JUQ-470 seems to be related to a particular product or item, possibly from a Japanese company.